Biogen Idec, Inc.

Genentech, Inc.

Biogen, Incorporated

Idec Pharmaceuticals Corporation

Christine A White

Antonio J Grillo-Lopez

John G Curd

Susan Desmond-Hellmann

William Raestetter

Antonio J Grillo-López

The present invention concerns methods for the treatment of diffuse large cell lymphoma by administration of an anti-CD20 antibody and chemotherapy. Particular embodiments include the administration of anti-CD20 antibody in combination with chemotherapy comprising CHOP (cyclophosphamide, hydroxydaunorubicin/doxorubicin, vincristine, and prednisone/prednisolone) and/or in combination with a transplantation regimen.

Treatment of diffuse large-cell lymphoma with anti-CD20 antibody

This invention concerns methods for the treatment of intermediate and high-grade non-Hodgkins lymphomas, comprising the administration of anti-CD20 monoclonal antibodies and fragments thereof. Particular embodiments include the administration of chimeric anti-CD20 antibody, either alone or in combination with radiolabeled antibodies or chemotherapy. The invention is particularly useful for lymphomas characterized by a high number of circulating B cells, possibly bone marrow involvement, bulky disease, or the involvement of extralymphatic organs or sites.

Treatment of aggressive non-Hodgkins lymphoma with anti-CD20 antibody

Chronic Lymphocytic Leukemia (CLL) may be treated with antibodies directed against the CD20 antigen.

Treatment of chronic lymphocytic leukemia using anti-CD20 antibodies

Treatment of hematologic malignancies associated with circulating tumor cells using chimeric anti-CD20 antibody

New clinical parameters are reported which may serve as predictors of the hematological toxicity associated with therapeutic radiolabeled antibodies, particularly those antibodies which target lymphoma cells which have a tendency to localize to the bone marrow.

Clinical parameters for determining hematologic toxicity prior to radioimmunotherapy

Treatment of B-cell associated diseases including autoimmune and B-cell malignancies such as leukemias, lymphomas, using the combination of an anti-CD20 antibody, preferably RITUXAN&#xae; and a radiolabeled anti-CD22 antibody, preferably anY labeled humanized anti-CD22 antibody, is described. These therapeutic regimens provide for enhanced depletion of B cells, and therefore reduce the risk in B cell malignancy treatment of relapse associated with RITUXAN&#xae; and, moreover, provide for prolonged immunosuppression of B-cell immune responses, especially in the context of autoimmune diseases and transplant.

Growing community of inventors

Rancho Santa Fe, CA, United States of America

Christine A White